Compounded Semaglutide vs.
Wegovy: Are They the Same?

When patients learn that compounded semaglutide costs a fraction of Wegovy's price, the first question is almost always whether it's really the same medication. The honest answer: fundamentally yes on the active ingredient, with real and important differences in how each is manufactured, regulated, and priced.

Same Active Ingredient, Different Manufacturing Path

Both compounded semaglutide and Wegovy contain semaglutide as the active molecule, working through the identical mechanism — GLP-1 receptor activation that reduces appetite, slows gastric emptying, and improves insulin sensitivity. Because the active ingredient is the same, the STEP clinical trial results (an average 14.9% body-weight reduction over 68 weeks at the 2.4mg maintenance dose) are directly relevant to what compounded semaglutide can achieve when patients follow the same dose-titration protocol and reach an equivalent maintenance dose.

Wegovy is manufactured by Novo Nordisk as a finished, FDA-approved drug product in large-scale facilities under Good Manufacturing Practice standards, then reviewed and approved by the FDA as a specific product. Compounded semaglutide is prepared by a licensed compounding pharmacy per individual prescription, using pharmaceutical-grade semaglutide from FDA-registered facilities — a fundamentally different manufacturing and regulatory pathway, even though the underlying molecule is the same and produces the same physiological effect at an equivalent dose.

How Quality Actually Gets Verified

Wegovy's quality control happens through the FDA's finished-drug approval process, including facility inspections, batch testing, and ongoing post-market surveillance specific to that approved product. Compounded semaglutide's quality control works differently: the compounding pharmacy itself is responsible for following USP (United States Pharmacopeia) standards for sterile and non-sterile compounding, and state boards of pharmacy conduct their own inspections of compounding facilities, separate from the FDA's finished-drug approval pathway.

This is a meaningfully different oversight model, not an absence of oversight. A patient evaluating a specific compounded product can reasonably ask for a certificate of analysis (COA) confirming the specific batch's potency and purity, something a legitimate compounding pharmacy should be able to provide on request. This isn't standard practice at every pharmacy, but it's a reasonable request that a transparent, quality-focused compounder should be willing to accommodate without hesitation or excessive delay.

It's worth noting that both pathways ultimately rely on some form of institutional oversight rather than the individual patient having to independently verify chemical purity themselves — the difference is which institution is doing the verifying (FDA for the finished product, state boards and USP standards for compounded preparations) and how that oversight is structured, documented, and made available to patients who ask.

When Compounded Semaglutide Is the More Appropriate Choice

Beyond simple cost preference, there are specific clinical scenarios where a personalized compounded formulation may be genuinely more appropriate than a standardized commercial product — a patient who needs a dose strength that doesn't align with Wegovy's fixed dosing increments, for example, or a patient with a documented allergy to an inactive ingredient in the commercial formulation. These represent the kind of individualized clinical justification the 503A compounding framework is specifically designed to accommodate, distinct from compounding purely for cost savings absent any other clinical rationale.

A thorough provider evaluation should document which specific rationale applies to your situation, whether that's a documented clinical need or, in the current regulatory environment, an acknowledgment that cost accessibility remains a genuine practical consideration for patients who would otherwise go without treatment entirely and forgo meaningful health benefits. This documentation isn't just a bureaucratic formality — it's the actual legal and clinical basis that makes your specific prescription appropriate under current 503A compounding rules and regulatory guidance.

The Legal Basis for Compounding

Compounded semaglutide is legally produced under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which allow licensed pharmacies to prepare medications, including patient-specific compounded versions of FDA-approved drugs, under defined conditions. This is distinct from the drug-shortage exception that also applied for a period when semaglutide was on the FDA's shortage list; 503A patient-specific compounding operates on its own legal basis rather than depending solely on shortage status. The regulatory landscape around bulk (503B) compounding of GLP-1 medications specifically has continued to evolve, which is part of why sourcing from a compounding pharmacy that's transparent about its licensing and process matters more than ever.

Following the FDA's determination that the semaglutide shortage resolved in February 2025, the legal basis for routine cost-driven compounding narrowed considerably, requiring a documented individual clinical justification rather than cost or convenience alone under 503A regulations specifically. Legitimate 503A compounding continues in 2026 under these narrower conditions, and the market has adjusted accordingly, with providers who take compliance seriously documenting appropriate clinical justification for each prescription rather than compounding purely as a lower-cost alternative to the branded product regardless of individual circumstances.

Cost Comparison

Wegovy's retail list price without insurance commonly runs $1,100-$1,350/month. Compounded semaglutide through licensed telehealth typically runs considerably lower — Luma Health's is $197/month, flat, regardless of dose. That price difference reflects the absence of large-scale manufacturing, marketing, and brand-drug development costs baked into Wegovy's pricing, not a difference in the core active ingredient.

With commercial insurance covering Wegovy and a manufacturer savings card applied, out-of-pocket cost can drop to as little as $25/month for eligible patients — potentially lower than compounded pricing in that specific best-case scenario, though this requires meeting the manufacturer's eligibility criteria. Without that coverage, compounded semaglutide is typically the substantially lower-cost path, which is the primary reason it has grown so quickly among cash-pay patients seeking affordable, ongoing access to treatment.

A Step-by-Step Guide to Verifying a Compounding Pharmacy

Before starting compounded semaglutide with any provider, a few concrete verification steps are worth taking. First, ask directly which specific pharmacy will prepare and dispense your medication — a legitimate provider should name it without hesitation. Second, look up that pharmacy's license status directly on the relevant state board of pharmacy's website (most states offer a searchable license lookup tool for this exact purpose), rather than relying solely on the provider's claim. Third, check whether the pharmacy holds any additional accreditations, such as PCAB (Pharmacy Compounding Accreditation Board) accreditation, which represents a voluntary, more rigorous quality standard beyond the baseline state licensing requirement most compounding pharmacies must meet.

These steps take only a few minutes but provide meaningfully more assurance than assuming a provider's marketing claims about "licensed pharmacies" are automatically accurate, current, or complete. This is especially worth doing given how quickly the compounded GLP-1 market has grown, alongside a corresponding increase in FDA and FBI warnings about counterfeit products and unlicensed sellers exploiting demand for lower-cost GLP-1 access among cash-pay patients specifically.

Dosing and Titration

Compounded semaglutide generally follows the same dose-titration schedule as Wegovy — starting around 0.25mg weekly and increasing gradually over several weeks to a maintenance dose (commonly 1.7mg or 2.4mg weekly) based on individual response and how well each dose increase is tolerated. This gradual approach exists to minimize gastrointestinal side effects regardless of which version you're taking.

One area where compounded formulations sometimes differ is dose flexibility — some compounding pharmacies can prepare doses at increments between Wegovy's fixed commercial strengths, which can be useful for patients whose provider wants to fine-tune a dose more precisely than the standardized product allows. This flexibility is one of the legitimate clinical reasons a compounded formulation might be appropriate beyond cost considerations alone, as discussed earlier in this comparison.

Which Path Fits You

Neither option is universally correct — the right choice depends on your insurance status, budget, and how much you weigh the FDA-approved finished-product status against the cost savings a compounded option can offer for your specific financial situation.

Frequently Asked Questions

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
2. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
3. U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide). FDA.gov. 2025. FDA Drug Approvals Database
4. U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
5. Texas State Board of Pharmacy. Pharmacy license lookup and verification. pharmacy.texas.gov